Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ViewRay, Inc.
  6. Summary
    VRAY   US92672L1070

VIEWRAY, INC.

(VRAY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/30/2021 08/02/2021 08/03/2021 08/04/2021 08/05/2021 Date
6.64(c) 6.66(c) 6.79(c) 6.78(c) 6.89 Last
696 062 511 501 642 937 1 631 062 2 327 184 Volume
-0.60% +0.30% +1.95% -0.15% +1.62% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 73,4 M - -
Net income 2021 -109 M - -
Net cash position 2021 95,5 M - -
P/E ratio 2021 -10,2x
Yield 2021 -
Sales 2022 118 M - -
Net income 2022 -103 M - -
Net cash position 2022 45,7 M - -
P/E ratio 2022 -10,9x
Yield 2022 -
Capitalization 1 114 M 1 114 M -
EV / Sales 2021 13,9x
EV / Sales 2022 9,05x
Nbr of Employees 236
Free-Float 96,5%
More Financials
Company
ViewRay Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian combines... 
More about the company
Ratings of ViewRay, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about VIEWRAY, INC.
05:36pVIEWRAY : Q2 Earnings Snapshot
AQ
04:15pVIEWRAY, INC. : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
04:13pVIEWRAY : Earnings Flash (VRAY) VIEWRAY Posts Q2 Revenue $15M, vs. Street Est of..
MT
04:02pVIEWRAY : Reports Second Quarter 2021 Results
PR
07/26INSIDER TRENDS : ViewRay Insider Tax Sale Continues 90-Day Selling Trend
MT
07/15VIEWRAY : Announces Conference Call for Second Quarter 2021 Financial Results to..
PR
07/07VIEWRAY : Miami Cancer Institute Enrolls First Patients in Single-Fraction Stere..
PR
07/07ViewRay, Inc. Announces That Miami Cancer Institute Enrolled First Patients i..
CI
06/28VIEWRAY : Morgan Stanley Lifts ViewRay to Equal-Weight From Underweight, Price T..
MT
06/25VIEWRAY : Oppenheimer Adjusts ViewRay PT to $8 From $6, Maintains Outperform Rat..
MT
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell 2000 Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell Microcap Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell 3000 Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell 3000E Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell Small Cap Comp Value Index
CI
More news
News in other languages on VIEWRAY, INC.

- No features available -

More news
Analyst Recommendations on VIEWRAY, INC.
More recommendations
Chart VIEWRAY, INC.
Duration : Period :
ViewRay, Inc. Technical Analysis Chart | VRAY | US92672L1070 | MarketScreener
Technical analysis trends VIEWRAY, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,89 $
Average target price 7,41 $
Spread / Average Target 7,49%
EPS Revisions
Managers and Directors
Scott William Drake President, Chief Executive Officer & Director
Zachary Stassen Chief Financial Officer
Daniel Jeffrey Moore Chairman
James F. Dempsey Chief Scientific Officer
Martin Fuss Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIEWRAY, INC.77.49%1 097
DANAHER CORPORATION37.58%218 182
THERMO FISHER SCIENTIFIC15.29%211 795
INTUITIVE SURGICAL, INC.21.12%117 665
SIEMENS HEALTHINEERS AG37.68%76 803
ILLUMINA, INC.34.71%73 672